Johnson & Johnson (JNJ) and Momenta Pharmaceuticals (MNTA) $6.5bn acquisition information including expected completion date, offer price and contact details are displayed in the acquisition details table below. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
This deal was successfully consummated on September 30, 2020
Momenta Pharmaceuticals (MNTA) Acquisition
Momenta Pharmaceuticals (NASDAQ: MNTA) Acquisition - Merger News and Events
The major acquisition news updates & events of Momenta Pharmaceuticals (MNTA) by Johnson & Johnson (JNJ) are listed below. A comprehensive data source for
- Traders looking to familiarize themselves with the Johnson & Johnson (JNJ) buyout of Momenta Pharmaceuticals (MNTA) and trade the merger arbitrage spread
- Existing shareholders and investors wishing to stay abreast of the latest deal developments.
Following the acquisition news section, there is an in-depth company profile.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn’s disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE.
The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
